Press releaseBusiness Wire
Revelation Biosciences
REVB · NASDAQ
$3.75+$3.28 (+699.06%)TodayMarket closed ·
Prev close $0.4693
Latest news
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releaseBusiness Wire
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
- Press releaseACCESS Newswire
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
- Press releaseACCESS Newswire
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
- Press releaseACCESS Newswire
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
- Press releaseACCESS Newswire
Revelation Biosciences Expands Acute Kidney Injury Advisory Board
- Press releaseACCESS Newswire
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
- News
Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation
- Press releaseACCESS Newswire
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
- Press releaseACCESS Newswire
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
- Press releaseACCESS Newswire
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study
- Press releaseACCESS Newswire
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
- News
Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation
- NewsVishaal Sanjay
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Decline After 2 Consecutive Days Of Gains—Intel, CSX In Focus (UPDATED)
- NewsAvi Kapoor
Why Ericsson Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releaseACCESS Newswire
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025
- News
Watching Revelation Bios; Zacks Small-Cap Research Gives Stock $21.45 Price Valuation
- Press releaseBusiness Wire
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025
- News
'CDER director Tidmarsh will be acting head of FDA biologics center following Prasad exit'- Endpoints News
- Press releaseBusiness Wire
Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research
- Press releaseBusiness Wire
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study
- News
Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $21.45/Share Valuation
- NewsRishabh Mishra
US Stocks Likely To Open Higher: S&P 500 Sees 'Average Gain Of 6.1%' In 2nd Half, Expert Says
- Press releaseBusiness Wire
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025
- NewsAvi Kapoor
Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
- Press releaseBusiness Wire
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering
- NewsAvi Kapoor
Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results
- NewsAvi Kapoor
Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseBusiness Wire
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering
- Press releaseBusiness Wire
Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors
- Press releaseBusiness Wire
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025
- Press releaseBusiness Wire
Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- Press releaseBusiness Wire
Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseBusiness Wire
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference
- Press releaseBusiness Wire
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024
- Press releaseBusiness Wire
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.